Moderna, Inc. $MRNA Shares Acquired by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 347.1% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 30,047 shares of the company’s stock after acquiring an additional 23,326 shares during the period. Motley Fool Asset Management LLC’s holdings in Moderna were worth $5,786,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Physician Wealth Advisors Inc. increased its stake in Moderna by 8.3% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock valued at $171,000 after buying an additional 68 shares during the last quarter. Fortitude Family Office LLC boosted its stake in shares of Moderna by 53.1% during the 3rd quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares during the last quarter. TD Waterhouse Canada Inc. boosted its stake in shares of Moderna by 2.6% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 3,388 shares of the company’s stock worth $246,000 after buying an additional 85 shares during the last quarter. SteelPeak Wealth LLC boosted its stake in shares of Moderna by 3.9% during the 3rd quarter. SteelPeak Wealth LLC now owns 3,397 shares of the company’s stock worth $654,000 after buying an additional 127 shares during the last quarter. Finally, Western Pacific Wealth Management LP bought a new position in shares of Moderna in the 3rd quarter valued at about $29,000. Institutional investors own 75.33% of the company’s stock.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Detailed Phase 3 data presented at ESMO 2026 showed that Moderna and Merck’s individualized mRNA melanoma vaccine, used with KEYTRUDA, significantly reduced disease recurrence and distant metastasis. The results were also accepted for publication in the New England Journal of Medicine, providing additional peer-reviewed validation. Moderna Gets Phase 3 Melanoma Vaccine Validation
• Positive Sentiment: CEO Stéphane Bancel said the cancer-vaccine data should improve as follow-up continues and argued that Moderna’s mRNA technology, manufacturing capabilities and personalized approach create a competitive advantage that rivals cannot easily replicate. He also expressed confidence that the platform could work beyond melanoma. Moderna CEO Defends Cancer Vaccine
• Neutral Sentiment: Investors are now looking beyond the clinical results to Moderna’s upcoming financial performance. Analysts broadly view the science favorably, but third-quarter revenue, cash use and the company’s path back to profitability remain key tests. Moderna ESMO Answered the Science
• Negative Sentiment: William Blair downgraded MRNA from Outperform to Market Perform, citing valuation after the stock’s very large rally. The call suggests that much of the cancer-vaccine opportunity may already be reflected in the share price, limiting near-term upside even if the clinical program succeeds. William Blair Downgrades Moderna on Valuation
• Negative Sentiment: The melanoma results, while clinically positive, reportedly fell short of some investors’ expectations, creating uncertainty about commercial uptake and contributing to volatility. Moderna also remains loss-making, with analysts expecting a full-year loss.

Moderna Stock Up 3.0%

MRNA stock opened at $214.16 on Thursday. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $254.48. The business’s 50 day simple moving average is $179.75 and its 200 day simple moving average is $84.64. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $85.50 billion, a PE ratio of -26.80 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter last year, the firm posted ($2.13) EPS. The company’s quarterly revenue was up 2.1% on a year-over-year basis. As a group, research analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current year.

Analyst Ratings Changes

MRNA has been the topic of a number of recent research reports. Morgan Stanley lifted their target price on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. TD Cowen restated a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Jefferies Financial Group reaffirmed a “hold” rating and set a $150.00 price target (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Moderna in a research note on Friday, August 28th. They set a “hold” rating and a $125.00 price objective on the stock. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $107.10.

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 40,294 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock valued at $33,875,904 over the last ninety days. 10.80% of the stock is currently owned by company insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.